Nivolumab for Breast Cancer

Phase-Based Progress Estimates
Breast CancerNivolumab - Drug
What conditions do you have?

Study Summary

This trial is testing a new cancer treatment that may improve Event Free Survival rates for women with a certain type of breast cancer.

Eligible Conditions
  • Breast Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 36 Months

36 Months
Distant Disease-Free Survival
Event-Free Survival
Invasive Disease-Free Survival
Overall Safety
Overall Survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Treatment Arm
1 of 1

Experimental Treatment

80 Total Participants · 1 Treatment Group

Primary Treatment: Nivolumab · No Placebo Group · Phase 2

Treatment ArmExperimental Group · 4 Interventions: Ipilimumab, Core Biopsy/Cryoablation, Nivolumab, Breast Surgery · Intervention Types: Drug, Procedure, Drug, Procedure
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 36 months

Who is running the clinical trial?

Heather McArthurLead Sponsor
Monica MitaLead Sponsor
2 Previous Clinical Trials
22 Total Patients Enrolled
2 Trials studying Breast Cancer
22 Patients Enrolled for Breast Cancer
Memorial Sloan Kettering Cancer CenterOTHER
1,832 Previous Clinical Trials
584,458 Total Patients Enrolled
192 Trials studying Breast Cancer
93,689 Patients Enrolled for Breast Cancer
Monica Mita, MDPrincipal InvestigatorCedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute
9 Previous Clinical Trials
369 Total Patients Enrolled
5 Trials studying Breast Cancer
202 Patients Enrolled for Breast Cancer
Heather McArthur, MDPrincipal InvestigatorUT Southwestern Medical Center
1 Previous Clinical Trials
174 Total Patients Enrolled
1 Trials studying Breast Cancer
174 Patients Enrolled for Breast Cancer

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Pathology confirmation of invasive carcinoma (reported or requested and pending).
You have a tumor measuring at least 1.0 cm in maximal diameter.